PDCD1 and neoplasm: Based on the above findings and our previous TORCH study, the treatment approach of combining PD-1 monotherapy with SCRT and chemotherapy is expected to remarkably improve tumour regression and CR rate, and provide more options for patients with early rectal cancer to achieve organ preservation.